id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-255791-ghrlj6b2	Pruijssers, Andrea J.	Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice	2020-04-27		.txt	text/plain	3444	219	57	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 as the causative agent of the novel pandemic viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for safe, broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 μM). These data provide evidence that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19. RDV and GS-441524 potently inhibited 110 SARS-CoV-2 replication in a dose-dependent manner in both cell types ( Fig. 2; Table 1 ). Together, these data demonstrate that RDV is potently antiviral 131 against SARS-CoV-2 in primary human lung cultures with a selectivity index of >1000.	./cache/cord-255791-ghrlj6b2.txt	./txt/cord-255791-ghrlj6b2.txt